700140Noninvasive glucose monitoring using breath analysisClosedGRD Proof of MarketInnovate UKDiabetes is one of the greatest health challenges the UK is facing, it is estimated that the number of people diagnosed with diabetes in the UK is 2.9 million and an estimated 850,000 people have the condition but don’t know it. By 2025 it is estimated that over four million. Most of these cases will be Type 2 diabetes, because of our ageing population and rapidly rising numbers of overweight and obese. The indirect costs of diabetes in the UK have been estimated to be close to £17 billion. Glucose monitoring is an essential requirement of disease management to achieve control. However, effective and routine monitoring remains a challenge for many diabetic patients primarily because of the invasive nature of available glucose monitoring devices. Invasive and painful monitoring is one of the main causes of poor patient compliance both with treatments and overall disease self-management. A low cost noninvasive test in a handheld device would be ideal for monitoring daily glucose levels without drawing blood. This type of non-invasive testing device would improve patient monitoring and lead to better self-management of this chronic disease. Breath analysis is an ideal a noninvasive test whereby small quantities of volatile compounds can be detected in human breath, and they can form a fingerprint that can be used for early disease detection and diagnosis. This would be an ideal test to screen patients and monitor the treatment of diabetes. Applied Nanodetectors has developed a breath chip that is being used for the diagnosis and control of asthma. This sensor chip could be configured to sense specific volatiles gases associated with blood sugar levels and then developed as a non-invasive test for diabetes screening and management. A non-invasive test has great commercial potential, however the market is very competitive and there are many commercial risks. In this project we plan to use market research to assess the commercial viability of a diabetes breath test.